No abstract available
MeSH terms
-
Acute Disease
-
Aged
-
Antibodies, Monoclonal, Humanized / adverse effects*
-
Anticoagulants / therapeutic use
-
Antineoplastic Agents / adverse effects*
-
Arterial Occlusive Diseases / chemically induced*
-
Arterial Occlusive Diseases / diagnosis
-
Arterial Occlusive Diseases / therapy
-
Computed Tomography Angiography
-
Diabetes Mellitus / blood
-
Diabetes Mellitus / chemically induced*
-
Diabetes Mellitus / diagnosis
-
Diabetes Mellitus / drug therapy
-
Embolectomy / methods
-
Humans
-
Hypoglycemic Agents / therapeutic use
-
Insulin / therapeutic use
-
Ischemia / chemically induced*
-
Ischemia / diagnosis
-
Ischemia / therapy
-
Lower Extremity / blood supply*
-
Male
-
Melanoma / drug therapy*
-
Melanoma / immunology
-
Melanoma / secondary
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
-
Programmed Cell Death 1 Receptor / immunology
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / immunology
-
Skin Neoplasms / pathology
-
Thrombosis / chemically induced*
-
Thrombosis / diagnosis
-
Thrombosis / therapy
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Humanized
-
Anticoagulants
-
Antineoplastic Agents
-
Hypoglycemic Agents
-
Insulin
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor
-
pembrolizumab